- Home
- FSHP vs CLSD Comparison
FSHP vs CLSD Comparison
Compare FSHP & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- CLSD
- Stock Information
- Founded
- FSHP 2018
- CLSD 2011
- Country
- FSHP United States
- CLSD United States
- Employees
- FSHP N/A
- CLSD N/A
- Industry
- FSHP
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- FSHP
- CLSD Health Care
- Exchange
- FSHP NYSE
- CLSD Nasdaq
- Market Cap
- FSHP 89.2M
- CLSD 76.6M
- IPO Year
- FSHP 2024
- CLSD 2016
- Fundamental
- Price
- FSHP $10.15
- CLSD $1.02
- Analyst Decision
- FSHP
- CLSD Strong Buy
- Analyst Count
- FSHP 0
- CLSD 6
- Target Price
- FSHP N/A
- CLSD $5.33
- AVG Volume (30 Days)
- FSHP 35.0K
- CLSD 230.0K
- Earning Date
- FSHP 01-01-0001
- CLSD 11-12-2024
- Dividend Yield
- FSHP N/A
- CLSD N/A
- EPS Growth
- FSHP N/A
- CLSD N/A
- EPS
- FSHP 0.11
- CLSD N/A
- Revenue
- FSHP N/A
- CLSD $7,703,000.00
- Revenue This Year
- FSHP N/A
- CLSD N/A
- Revenue Next Year
- FSHP N/A
- CLSD $91.87
- P/E Ratio
- FSHP $89.28
- CLSD N/A
- Revenue Growth
- FSHP N/A
- CLSD 248.39
- 52 Week Low
- FSHP $9.99
- CLSD $0.92
- 52 Week High
- FSHP $10.16
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- CLSD 42.14
- Support Level
- FSHP N/A
- CLSD $0.99
- Resistance Level
- FSHP N/A
- CLSD $1.05
- Average True Range (ATR)
- FSHP 0.00
- CLSD 0.05
- MACD
- FSHP 0.00
- CLSD 0.00
- Stochastic Oscillator
- FSHP 0.00
- CLSD 15.38
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.